Literature DB >> 20815661

Adherence to controller therapy for chronic obstructive pulmonary disease: a review.

Meaghan St Charles1, Christopher M Blanchette, Harris Silver, Danielle Lavallee, Anand A Dalal, Douglas Mapel.   

Abstract

OBJECTIVE: While several studies have examined adherence to controller medications for the treatment of COPD, few systematic reviews have taken the translational step to identifying important and necessary areas for further research. The objective of this study was to review data on the outcomes of adherence to various controller therapies in patients with COPD in an effort to help prescribers understand adherence properties for each therapy. RESEARCH DESIGN AND METHODS: This is a systematic review of studies investigating adherence to an array of controller pharmaceutical regimens. The studies were obtained from PubMed during 2008 and 2009 using the following key words: chronic obstructive pulmonary disease, COPD, adherence, controller medication, and persistence. Only articles encompassing adherence or persistence data to controller medications and published after 1990 were utilized.
RESULTS: After the search results were filtered for only the articles that pertained to adherence or persistence measurements in COPD, 35 articles remained; and finally, discounting those articles not published in English, articles which did not compare treatments for COPD, as well as those which were review articles, ten applicable articles remained. Each of these found low levels of medication adherence and/or persistence among patients receiving medications for COPD. Patients receiving fluticasone/salmeterol (FSC) and tiotropium (TIO) for treatment showed the highest adherence among all controller medications. Patients who were married, older, and white were more likely to adhere to their medications.
CONCLUSION: Characteristics of the medication used (i.e. dosing schedule, formulation, etc.) as well as patient characteristics affect the adherence/persistence to medications for the treatment of COPD. Further patient education is necessary in order to effectively improve disease management and patient outcomes in COPD. There is a need for future research and educational efforts to improve adherence in COPD and more clearly identify specific behavioral and treatment characteristics associated with specific COPD medications that can facilitate adherence.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20815661     DOI: 10.1185/03007995.2010.516284

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  20 in total

Review 1.  An American Thoracic Society/National Heart, Lung, and Blood Institute Workshop Report: Addressing Respiratory Health Equality in the United States.

Authors:  Juan C Celedón; Esteban G Burchard; Dean Schraufnagel; Carlos Castillo-Salgado; Marc Schenker; John Balmes; Enid Neptune; Kristin J Cummings; Fernando Holguin; Kristin A Riekert; Juan P Wisnivesky; Joe G N Garcia; Jesse Roman; Rick Kittles; Victor E Ortega; Susan Redline; Rasika Mathias; Al Thomas; Jonathan Samet; Jean G Ford
Journal:  Ann Am Thorac Soc       Date:  2017-05

Review 2.  Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.

Authors:  Agnieszka Sliwka; Milosz Jankowski; Iwona Gross-Sondej; Monika Storman; Roman Nowobilski; Malgorzata M Bala
Journal:  Cochrane Database Syst Rev       Date:  2018-08-24

Review 3.  Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the Trend.

Authors:  Christopher M Blanchette; Nicholas J Gross; Pablo Altman
Journal:  Am Health Drug Benefits       Date:  2014-04

Review 4.  Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease.

Authors:  Natalie J Carter
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

5.  Association between depression and maintenance medication adherence among Medicare beneficiaries with chronic obstructive pulmonary disease.

Authors:  Jingjing Qian; Linda Simoni-Wastila; Gail B Rattinger; Ilene H Zuckerman; Susan Lehmann; Yu-Jung J Wei; Bruce Stuart
Journal:  Int J Geriatr Psychiatry       Date:  2013-04-19       Impact factor: 3.485

6.  Assessing the stages of the grieving process in chronic obstructive pulmonary disease (COPD): validation of the Acceptance of Disease and Impairments Questionnaire (ADIQ).

Authors:  Lonneke M Boer; Leonie Daudey; Jeannette B Peters; Johan Molema; Judith B Prins; Jan H Vercoulen
Journal:  Int J Behav Med       Date:  2014-06

Review 7.  Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol.

Authors:  Timothy E Albertson; Richart Harper; Susan Murin; Christian Sandrock
Journal:  Patient Prefer Adherence       Date:  2015-02-02       Impact factor: 2.711

Review 8.  Management of asthma and chronic obstructive pulmonary disease with combination inhaled corticosteroids and long-acting β-agonists: a review of comparative effectiveness research.

Authors:  Douglas W Mapel; Melissa H Roberts
Journal:  Drugs       Date:  2014-05       Impact factor: 9.546

9.  Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD.

Authors:  Henrik Svedsater; Peter Dale; Karl Garrill; Richard Walker; Mark W Woepse
Journal:  BMC Pulm Med       Date:  2013-12-07       Impact factor: 3.317

Review 10.  COPD: adherence to therapy.

Authors:  Alessandro Sanduzzi; Piero Balbo; Piero Candoli; Giousuè A Catapano; Paola Contini; Alessio Mattei; Giovanni Puglisi; Luigi Santoiemma; Anna A Stanziola
Journal:  Multidiscip Respir Med       Date:  2014-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.